Combination of 4-1BB agonist and PD-1 antagonist could promote anti-tumor effector/memory response of CD8 T cells in a poorly immunogenic B16 model (29) and ovarian cancer model (30). Here, TNFRSF9 is linked to ovarian carcinoma.